News from janssen r A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Feb 12, 2015, 06:15 ET

Janssen Sets A Course To Intercept Type 1 Diabetes Together With JDRF

Janssen Research & Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it...

Feb 12, 2015, 06:00 ET

Janssen Launches Three New Research Platforms Focused on Redefining Healthcare

 Janssen Research & Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today the...

Feb 09, 2015, 06:00 ET
Janssen Logo.  (PRNewsFoto/Janssen Pharmaceutical Companies)

La CE aprueba la indicación adicional para VELCADE® (bortezomib) en linfoma de células del manto

Este comunicado de prensa está originalmente escrito en inglés. PR Newswire proporciona las traducciones en alemán, francés y...

Feb 09, 2015, 05:58 ET
Janssen Logo.  (PRNewsFoto/Janssen Pharmaceutical Companies)

La Commission européenne approuve une indication supplémentaire pour VELCADE® (bortézomib) sur le lymphome à cellules du manteau

Ce communiqué de presse a été rédigé en Anglais. Des traductions en Allemand, Français et Espagnol sont fournies...

Feb 06, 2015, 13:12 ET
Janssen Logo.  (PRNewsFoto/Janssen Pharmaceutical Companies)

EU-Kommission genehmigt weitere Indikation für VELCADE® (Bortezomib) bei Mantelzell-Lymphomen

- Die Originalsprache dieser Pressemitteilung ist Englisch. Übersetzungen ins Deutsche, Französische und Spanische werden von PR...

Feb 03, 2015, 03:30 ET

U.S. FDA Grants Priority Review for YONDELIS® (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma

Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review...

Jan 29, 2015, 16:17 ET
PREZCOBIX(TM) (darunavir 800mg / cobicistat 150mg) Tablets

PREZCOBIX™ (darunavir/cobicistat) Approved in the U.S. for the Treatment of Adults Living With HIV-1

Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the U.S. Food and Drug Administration (FDA) has approved...

Jan 29, 2015, 11:48 ET

U.S. FDA Approves IMBRUVICA® (ibrutinib) for the Treatment of Waldenstrom's Macroglobulinemia: First FDA-Approved Therapy for This Disease

Janssen Biotech, Inc. ("Janssen") today announced that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA®...

Jan 19, 2015, 10:00 ET

FDA Grants Priority Review for Three-Month Paliperidone Palmitate for the Treatment of Schizophrenia

Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for...

Jan 15, 2015, 16:05 ET

Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest U.S. License Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended-release tablets and NUCYNTA® (tapentadol) Oral Solution

Janssen Pharmaceuticals, Inc. (JPI) today announced it has entered into a definitive agreement with Depomed, Inc. to divest its U.S. license rights...

Jan 14, 2015, 09:45 ET

Real-World Data Published in Clinical Cardiology Show Consistent Safety Performance of Once-Daily XARELTO®

A new post-marketing study evaluating the safety of once-daily XARELTO® (rivaroxaban) shows, in patients with non-valvular atrial fibrillation...

Dec 29, 2014, 08:30 ET
Janssen Logo.  (PRNewsFoto/Janssen Pharmaceutical Companies)

Janssen Announces Collaboration with Gilead to Develop PREZISTA®-based Single-tablet Regimen for the Treatment of People Living with HIV

-- Two Companies to also Collaborate on the Further Development of Complera®, Marketed as Eviplera® in the European Union...

Dec 23, 2014, 04:48 ET
Janssen Logo.  (PRNewsFoto/Janssen Pharmaceutical Companies)

Janssen erhält positive Beurteilung: Der CHMP empfiehlt VELCADE® (Bortezomib) zum Einsatz bei Mantelzell-Lymphomen

Die Originalsprache dieser Pressemitteilung ist Englisch. Übersetzungen ins Deutsche, Französische und Spanische werden von PR Newswire...

Dec 23, 2014, 04:46 ET
Janssen Logo.  (PRNewsFoto/Janssen Pharmaceutical Companies)

Janssen reçoit un avis du CHMP favorable à l'approbation de VELCADE® (bortézomib) dans le cadre du traitement du lymphome à cellules du manteau

  Ce communiqué de presse a été rédigé en Anglais.  Des traductions en Allemand, Français et Espagnol...

Dec 22, 2014, 10:53 ET
Janssen Logo.  (PRNewsFoto/Janssen Pharmaceutical Companies)

Janssen recibe la opinión positiva del CHMP recomendando VELCADE® (bortezomib) para uso en linfomas de células del manto

Este comunicado de prensa está originalmente escrito en inglés. PR Newswire proporciona las traducciones en alemán, francés y...

Dec 12, 2014, 12:15 ET

Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium

 Janssen Research & Development, LLC (Janssen) today announced the presentation of data at the San Antonio Breast Cancer Symposium...

Dec 10, 2014, 08:05 ET
Dec 10, 2014, 08:02 ET
Janssen Logo.  (PRNewsFoto/Janssen Pharmaceutical Companies)

Neue auf der ASH-Tagung vorgestellte Nachbeobachtungsdaten für IMBRUVICA® (Ibrutinib) belegen längerfristige Wirksamkeit bei Patienten mit chronischer lymphozytischer Leukämie und Mantelzelllymphom

Die Originalsprache dieser Pressemitteilung ist Englisch. Übersetzungen ins Deutsche, Französische und Spanische werden von PR Newswire...

Dec 08, 2014, 21:33 ET

IMBRUVICA® (ibrutinib) Long-term Follow-up Data in Patients Living with Relapsed/Refractory Mantle Cell Lymphoma Show Almost Half Alive at Two Years

 New data presented today at the American Society of Hematology (ASH) Annual Meeting in San Francisco, CA, suggest the current safety and...